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Introduction
Pompe disease (glycogenosis II, acid maltase deficiency,
OMIM 232300) is a treatable autosomal recessive disor-
der of glycogen metabolism caused by deficiency of the
lysosomal enzyme acid alpha-glucosidase. A hallmark of
Pompe disease is the presence of glycogen-loaded lyso-
somes. Pompe disease has frequently been misdiagnosed
as other myopathies, such as polymyositis, and mista-
kenly treated with steroids. A rheumatology based prac-
tice survey is being designed to establish the incidence
of Pompe disease and other myopathies in patients with
atypical steroid-unresponsive presumed myopathies
(ASUPM).
Methods
Five to ten self-identified rheumatologists with an inter-
est in myopathies and ‘community’ practices located in
Ontario, Canada, will review medical records to identify
patients with ASUPM. A standardized chart review tool
to help expedite the review will be developed and
approved by the participants. Charts of any patient seen
in the past five years with a diagnostic code of 710, 729,
739 or 781 will be identified and data extracted using the
standardized CRF; data extraction will be performed by
the physician or a trained delegate. Central IRB approval
will be obtained, and participants will be eligible for CPD
credits. Physicians will also provide demographic infor-
mation (i.e., years in practice, practice profile, total charts
reviewed, etc.), and patient data will include, but is not
limited to the following: CK values, serology findings,
biopsy results, steroid responsiveness, and diagnoses (e.g.,
polymyositis, dermatomyositis). Identified patients will be
referred to a single neuromuscular practitioner (Mark
Tarnopolsky) who will perform dried blood spot, enzy-
matic, and genetic tests to determine the exact nature of
the myopathy and the incidence and prevalence of these
steroid non-responsive myopathies in the ASUPM
population.
Discussion
Presentation at the 6th Annual European Symposium will
provide an opportunity for us to further develop this pro-
ject based on expert feedback. Our overarching goals are
to: 1) develop strategies/tools to facilitate efficient, sys-
tematic chart review; 2) ascertain cases of atypical myopa-
thy/myositis or other unclear diagnoses that may be
Pompe disease; 3) improve physician awareness of uncom-
mon and rare diagnoses; and 4) share the results with a
wider rheumatology community.
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